Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tonix Pharma ( (TNXP) ) just unveiled an update.
On March 10, 2026, Tonix Pharmaceuticals reported new clinical data on TONMYA (cyclobenzaprine HCl sublingual tablets) from two oral presentations at the 8th International Congress on Controversies in Fibromyalgia. The first presentation detailed results from the 14-week Phase 3 RESILIENT trial in 457 adults, showing rapid and statistically significant reductions in fibromyalgia pain versus placebo starting by Day 2 and sustained through Week 14, with all key secondary endpoints favoring TONMYA.
The second presentation pooled data from the RELIEF and RESILIENT Phase 3 trials, covering 959 participants, to clarify TONMYA’s benefit-risk profile using number needed to treat and harm metrics. The analysis found an NNT of 7 for achieving at least a 30% pain reduction over placebo at Week 14 and an NNH of 26 for discontinuation due to adverse events, yielding a likelihood to be helped or harmed of 3.7, indicating a substantially greater chance of clinical benefit than treatment-limiting side effects for fibromyalgia patients.
The most recent analyst rating on (TNXP) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
The score is held down primarily by weak financial performance (losses and cash burn) and bearish technicals (below major moving averages with negative MACD). Positive corporate developments (commercial launch and regulatory/pipeline progress) provide support but do not fully offset the current profitability and trend risks; valuation is difficult to assess due to negative earnings.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing therapies for central nervous system disorders, including fibromyalgia. Its pipeline includes TONMYA, a sublingual formulation of cyclobenzaprine hydrochloride being evaluated as a treatment to provide rapid pain relief for adults with fibromyalgia.
Average Trading Volume: 406,267
Technical Sentiment Signal: Strong Sell
Current Market Cap: $178.3M
For a thorough assessment of TNXP stock, go to TipRanks’ Stock Analysis page.